Pergolide in the treatment of parkinson's disease

Yoshikuni Mizuno; Tomoyoshi Kondo; Hirotaro Narabayashi; Y. Mizuno; H. Mori; T. Kondo; D. B. Calne; P. F. Teychenne; L. E. Claveria; A. E. Lang; N. Quinn; S. Drincat; A. Lieberman; M. Goldstein; M. Leibowitz; G. Gopinathan; H. Teravainen; J. M. Dambrosia; P. A. Lewitt; G. Gopinathan; C. D. Ward; M. Goldstein; A. Lieberman; J. Y. Lew; J. E. Ahlskog; M. D. Muenter; J. Jankovic; R. Kurlan; C. Millar; R. Knapp; H. Narabayashi; K. Ando; H. Kowa; C. W. Olanow; M. J. Alberts; J. I. Sage; R. C. Duvoisin; H. Narabayashi; K. Ando; H. Kowa; T. Mannen; Y. Mizuno; M. Iwata; S. G. Diamond; C. H. Markham; L. J. Treciokas; J. E. Ahlskog; M. D. Muenter; P. Jeanty; M. Van Den Kerchove; A. Lowenthal; J. I. Sage; R. C. Duvoisin; J. Jankovic; A. N. Lieberman; M. Goldstein; M. Leibowitz; R. Kurlan; C. Millar; R. Levy; D. L. Kleinberg; A. Lieberman; J. Todd; C. G. Goetz; C. M. Tanner; R. Glantz; A. Lieberman; L. Chin; G. Baumann; J. E. Ahlskog; M. D. Muenter; P. A. Bailey; S. A. Factor; J. R. Sanchez-Ramos; W. J. Weiner; P. A. Nausieda; W. J. Weiner; H. L. Klawans; M. M.M. Hoehn; R. L. Elton; A. J. Lees; G. M. Stern; Y. Agid; P. Pollak; A. M. Bonnet; M. Leibowitz; A. N. Lieberman; A. Neophytides; U. K. Rinne; J. F. Demonet; M. Rostin; A. Dueymes Ioualalen; P. A. Lewitt; C. D. Ward; T. A. Larsen; C. G. Goetz; C. M. Tanner; R. Glantz; C. G. Goetz; K. M. Shannon; C. M. Tanner; A. N. Lieberman; M. Goldstein; G. Gopinathan; A. N. Lieberman; N. Leibowitz; G. Gopinathan; M. A. Hely; J. G.L. Morris; D. D. Rail; T. Nakanishi; Y. Mizuno; I. Goto; T. Nakanishi; M. Iwata; I. Goto; A. Rascol; J. L. Montastruc; O. Rascol; U. K. Rinne; U. K. Rinne; W. J. Weiner; S. A. Factor; J. R. Sanchez-Ramos; D. L. Felten; S. Y. Felten; R. W. Fuller; T. Yoshikawa

doi:10.1212/wnl.45.3_suppl_3.s13

Pergolide in the treatment of parkinson's disease

Yoshikuni Mizuno, Tomoyoshi Kondo, Hirotaro Narabayashi, Y. Mizuno, H. Mori, T. Kondo, D. B. Calne, P. F. Teychenne, L. E. Claveria, A. E. Lang, N. Quinn, S. Drincat, A. Lieberman, M. Goldstein, M. Leibowitz, G. Gopinathan, H. Teravainen, J. M. Dambrosia, P. A. Lewitt, G. GopinathanC. D. Ward, M. Goldstein, A. Lieberman, J. Y. Lew, J. E. Ahlskog, M. D. Muenter, J. Jankovic, R. Kurlan, C. Millar, R. Knapp, H. Narabayashi, K. Ando, H. Kowa, C. W. Olanow, M. J. Alberts, J. I. Sage, R. C. Duvoisin, H. Narabayashi, K. Ando, H. Kowa, T. Mannen, Y. Mizuno, M. Iwata, S. G. Diamond, C. H. Markham, L. J. Treciokas, J. E. Ahlskog, M. D. Muenter, P. Jeanty, M. Van Den Kerchove, A. Lowenthal, J. I. Sage, R. C. Duvoisin, J. Jankovic, A. N. Lieberman, M. Goldstein, M. Leibowitz, R. Kurlan, C. Millar, R. Levy, D. L. Kleinberg, A. Lieberman, J. Todd, C. G. Goetz, C. M. Tanner, R. Glantz, A. Lieberman, L. Chin, G. Baumann, J. E. Ahlskog, M. D. Muenter, P. A. Bailey, S. A. Factor, J. R. Sanchez-Ramos, W. J. Weiner, P. A. Nausieda, W. J. Weiner, H. L. Klawans, M. M.M. Hoehn, R. L. Elton, A. J. Lees, G. M. Stern, Y. Agid, P. Pollak, A. M. Bonnet, M. Leibowitz, A. N. Lieberman, A. Neophytides, U. K. Rinne, J. F. Demonet, M. Rostin, A. Dueymes Ioualalen, P. A. Lewitt, C. D. Ward, T. A. Larsen, C. G. Goetz, C. M. Tanner, R. Glantz, C. G. Goetz, K. M. Shannon, C. M. Tanner, A. N. Lieberman, M. Goldstein, G. Gopinathan, A. N. Lieberman, N. Leibowitz, G. Gopinathan, M. A. Hely, J. G.L. Morris, D. D. Rail, T. Nakanishi, Y. Mizuno, I. Goto, T. Nakanishi, M. Iwata, I. Goto, A. Rascol, J. L. Montastruc, O. Rascol, U. K. Rinne, U. K. Rinne, W. J. Weiner, S. A. Factor, J. R. Sanchez-Ramos, D. L. Felten, S. Y. Felten, R. W. Fuller, T. Yoshikawa

Research output: Contribution to journal › Article › peer-review

106 Scopus citations

Abstract

Three trials evaluated the efficacy and safety of pergolide.Eighty-six de novo patients and 314 patients already receiving levodopa were enrolled in an open-label study. Of the de novo patients, 47.5% showed a marked or moderate improvement and 32% showed a mild improvement. In the levodopa add-on group, 53.8% showed marked or moderate improvement and 36.3% showed mild improvement. In a short-term, double-blind study, the efficacy of pergolide was compared with that of bromocriptine. One hundred seventy-two patients were randomized to receive pergolide, and 173 were randomized to receive bromocriptine. In de novo patients, bromocriptine (n equals 49) and pergolide (n equals 49) demonstrated similar efficacy. However, significantly more levodopa-treated patients in the pergolide group, compared with the bromocriptine group, demonstrated marked or moderate improvements in several items of the rating scale score. In a long-term study, 151 of 314 patients receiving pergolide in combination with levodopa remained in the study for 3 years, and 127 for 4 years, and in these patients the initial improvement was maintained. In 18 of 62 de novo patients, the initial improvement was maintained for up to 3 years. These trials indicate that pergolide has efficacy in patients with Parkinson's disease, either as monotherapy or in combination with levodopa.

Original language	English (US)
Pages (from-to)	S13-S21
Journal	Neurology
Volume	45
Issue number	3
DOIs	https://doi.org/10.1212/wnl.45.3_suppl_3.s13
State	Published - Mar 1 1995

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/wnl.45.3_suppl_3.s13

Cite this

Mizuno, Y., Kondo, T., Narabayashi, H., Mizuno, Y., Mori, H., Kondo, T., Calne, D. B., Teychenne, P. F., Claveria, L. E., Lang, A. E., Quinn, N., Drincat, S., Lieberman, A., Goldstein, M., Leibowitz, M., Gopinathan, G., Teravainen, H., Dambrosia, J. M., Lewitt, P. A., ... Yoshikawa, T. (1995). Pergolide in the treatment of parkinson's disease. Neurology, 45(3), S13-S21. https://doi.org/10.1212/wnl.45.3_suppl_3.s13

Mizuno, Y, Kondo, T, Narabayashi, H, Mizuno, Y, Mori, H, Kondo, T, Calne, DB, Teychenne, PF, Claveria, LE, Lang, AE, Quinn, N, Drincat, S, Lieberman, A, Goldstein, M, Leibowitz, M, Gopinathan, G, Teravainen, H, Dambrosia, JM, Lewitt, PA, Gopinathan, G, Ward, CD, Goldstein, M, Lieberman, A, Lew, JY, Ahlskog, JE, Muenter, MD, Jankovic, J, Kurlan, R, Millar, C, Knapp, R, Narabayashi, H, Ando, K, Kowa, H, Olanow, CW, Alberts, MJ, Sage, JI, Duvoisin, RC, Narabayashi, H, Ando, K, Kowa, H, Mannen, T, Mizuno, Y, Iwata, M, Diamond, SG, Markham, CH, Treciokas, LJ, Ahlskog, JE, Muenter, MD, Jeanty, P, Van Den Kerchove, M, Lowenthal, A, Sage, JI, Duvoisin, RC, Jankovic, J, Lieberman, AN, Goldstein, M, Leibowitz, M, Kurlan, R, Millar, C, Levy, R, Kleinberg, DL, Lieberman, A, Todd, J, Goetz, CG, Tanner, CM, Glantz, R, Lieberman, A, Chin, L, Baumann, G, Ahlskog, JE, Muenter, MD, Bailey, PA, Factor, SA, Sanchez-Ramos, JR, Weiner, WJ, Nausieda, PA, Weiner, WJ, Klawans, HL, Hoehn, MMM, Elton, RL, Lees, AJ, Stern, GM, Agid, Y, Pollak, P, Bonnet, AM, Leibowitz, M, Lieberman, AN, Neophytides, A, Rinne, UK, Demonet, JF, Rostin, M, Dueymes Ioualalen, A, Lewitt, PA, Ward, CD, Larsen, TA, Goetz, CG, Tanner, CM, Glantz, R, Goetz, CG, Shannon, KM, Tanner, CM, Lieberman, AN, Goldstein, M, Gopinathan, G, Lieberman, AN, Leibowitz, N, Gopinathan, G, Hely, MA, Morris, JGL, Rail, DD, Nakanishi, T, Mizuno, Y, Goto, I, Nakanishi, T, Iwata, M, Goto, I, Rascol, A, Montastruc, JL, Rascol, O, Rinne, UK, Rinne, UK, Weiner, WJ, Factor, SA, Sanchez-Ramos, JR, Felten, DL, Felten, SY, Fuller, RW & Yoshikawa, T 1995, 'Pergolide in the treatment of parkinson's disease', Neurology, vol. 45, no. 3, pp. S13-S21. https://doi.org/10.1212/wnl.45.3_suppl_3.s13

@article{3265707bac2548749bf4d5927cf27a50,

title = "Pergolide in the treatment of parkinson's disease",

abstract = "Three trials evaluated the efficacy and safety of pergolide.Eighty-six de novo patients and 314 patients already receiving levodopa were enrolled in an open-label study. Of the de novo patients, 47.5% showed a marked or moderate improvement and 32% showed a mild improvement. In the levodopa add-on group, 53.8% showed marked or moderate improvement and 36.3% showed mild improvement. In a short-term, double-blind study, the efficacy of pergolide was compared with that of bromocriptine. One hundred seventy-two patients were randomized to receive pergolide, and 173 were randomized to receive bromocriptine. In de novo patients, bromocriptine (n equals 49) and pergolide (n equals 49) demonstrated similar efficacy. However, significantly more levodopa-treated patients in the pergolide group, compared with the bromocriptine group, demonstrated marked or moderate improvements in several items of the rating scale score. In a long-term study, 151 of 314 patients receiving pergolide in combination with levodopa remained in the study for 3 years, and 127 for 4 years, and in these patients the initial improvement was maintained. In 18 of 62 de novo patients, the initial improvement was maintained for up to 3 years. These trials indicate that pergolide has efficacy in patients with Parkinson's disease, either as monotherapy or in combination with levodopa.",

author = "Yoshikuni Mizuno and Tomoyoshi Kondo and Hirotaro Narabayashi and Y. Mizuno and H. Mori and T. Kondo and Calne, {D. B.} and Teychenne, {P. F.} and Claveria, {L. E.} and Lang, {A. E.} and N. Quinn and S. Drincat and A. Lieberman and M. Goldstein and M. Leibowitz and G. Gopinathan and H. Teravainen and Dambrosia, {J. M.} and Lewitt, {P. A.} and G. Gopinathan and Ward, {C. D.} and M. Goldstein and A. Lieberman and Lew, {J. Y.} and Ahlskog, {J. E.} and Muenter, {M. D.} and J. Jankovic and R. Kurlan and C. Millar and R. Knapp and H. Narabayashi and K. Ando and H. Kowa and Olanow, {C. W.} and Alberts, {M. J.} and Sage, {J. I.} and Duvoisin, {R. C.} and H. Narabayashi and K. Ando and H. Kowa and T. Mannen and Y. Mizuno and M. Iwata and Diamond, {S. G.} and Markham, {C. H.} and Treciokas, {L. J.} and Ahlskog, {J. E.} and Muenter, {M. D.} and P. Jeanty and {Van Den Kerchove}, M. and A. Lowenthal and Sage, {J. I.} and Duvoisin, {R. C.} and J. Jankovic and Lieberman, {A. N.} and M. Goldstein and M. Leibowitz and R. Kurlan and C. Millar and R. Levy and Kleinberg, {D. L.} and A. Lieberman and J. Todd and Goetz, {C. G.} and Tanner, {C. M.} and R. Glantz and A. Lieberman and L. Chin and G. Baumann and Ahlskog, {J. E.} and Muenter, {M. D.} and Bailey, {P. A.} and Factor, {S. A.} and Sanchez-Ramos, {J. R.} and Weiner, {W. J.} and Nausieda, {P. A.} and Weiner, {W. J.} and Klawans, {H. L.} and Hoehn, {M. M.M.} and Elton, {R. L.} and Lees, {A. J.} and Stern, {G. M.} and Y. Agid and P. Pollak and Bonnet, {A. M.} and M. Leibowitz and Lieberman, {A. N.} and A. Neophytides and Rinne, {U. K.} and Demonet, {J. F.} and M. Rostin and {Dueymes Ioualalen}, A. and Lewitt, {P. A.} and Ward, {C. D.} and Larsen, {T. A.} and Goetz, {C. G.} and Tanner, {C. M.} and R. Glantz and Goetz, {C. G.} and Shannon, {K. M.} and Tanner, {C. M.} and Lieberman, {A. N.} and M. Goldstein and G. Gopinathan and Lieberman, {A. N.} and N. Leibowitz and G. Gopinathan and Hely, {M. A.} and Morris, {J. G.L.} and Rail, {D. D.} and T. Nakanishi and Y. Mizuno and I. Goto and T. Nakanishi and M. Iwata and I. Goto and A. Rascol and Montastruc, {J. L.} and O. Rascol and Rinne, {U. K.} and Rinne, {U. K.} and Weiner, {W. J.} and Factor, {S. A.} and Sanchez-Ramos, {J. R.} and Felten, {D. L.} and Felten, {S. Y.} and Fuller, {R. W.} and T. Yoshikawa",

year = "1995",

month = mar,

day = "1",

doi = "10.1212/wnl.45.3_suppl_3.s13",

language = "English (US)",

volume = "45",

pages = "S13--S21",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Pergolide in the treatment of parkinson's disease

AU - Mizuno, Yoshikuni

AU - Kondo, Tomoyoshi

AU - Narabayashi, Hirotaro

AU - Mizuno, Y.

AU - Mori, H.

AU - Kondo, T.

AU - Calne, D. B.

AU - Teychenne, P. F.

AU - Claveria, L. E.

AU - Lang, A. E.

AU - Quinn, N.

AU - Drincat, S.

AU - Lieberman, A.

AU - Goldstein, M.

AU - Leibowitz, M.

AU - Gopinathan, G.

AU - Teravainen, H.

AU - Dambrosia, J. M.

AU - Lewitt, P. A.

AU - Gopinathan, G.

AU - Ward, C. D.

AU - Goldstein, M.

AU - Lieberman, A.

AU - Lew, J. Y.

AU - Ahlskog, J. E.

AU - Muenter, M. D.

AU - Jankovic, J.

AU - Kurlan, R.

AU - Millar, C.

AU - Knapp, R.

AU - Narabayashi, H.

AU - Ando, K.

AU - Kowa, H.

AU - Olanow, C. W.

AU - Alberts, M. J.

AU - Sage, J. I.

AU - Duvoisin, R. C.

AU - Narabayashi, H.

AU - Ando, K.

AU - Kowa, H.

AU - Mannen, T.

AU - Mizuno, Y.

AU - Iwata, M.

AU - Diamond, S. G.

AU - Markham, C. H.

AU - Treciokas, L. J.

AU - Ahlskog, J. E.

AU - Muenter, M. D.

AU - Jeanty, P.

AU - Van Den Kerchove, M.

AU - Lowenthal, A.

AU - Sage, J. I.

AU - Duvoisin, R. C.

AU - Jankovic, J.

AU - Lieberman, A. N.

AU - Goldstein, M.

AU - Leibowitz, M.

AU - Kurlan, R.

AU - Millar, C.

AU - Levy, R.

AU - Kleinberg, D. L.

AU - Lieberman, A.

AU - Todd, J.

AU - Goetz, C. G.

AU - Tanner, C. M.

AU - Glantz, R.

AU - Lieberman, A.

AU - Chin, L.

AU - Baumann, G.

AU - Ahlskog, J. E.

AU - Muenter, M. D.

AU - Bailey, P. A.

AU - Factor, S. A.

AU - Sanchez-Ramos, J. R.

AU - Weiner, W. J.

AU - Nausieda, P. A.

AU - Weiner, W. J.

AU - Klawans, H. L.

AU - Hoehn, M. M.M.

AU - Elton, R. L.

AU - Lees, A. J.

AU - Stern, G. M.

AU - Agid, Y.

AU - Pollak, P.

AU - Bonnet, A. M.

AU - Leibowitz, M.

AU - Lieberman, A. N.

AU - Neophytides, A.

AU - Rinne, U. K.

AU - Demonet, J. F.

AU - Rostin, M.

AU - Dueymes Ioualalen, A.

AU - Lewitt, P. A.

AU - Ward, C. D.

AU - Larsen, T. A.

AU - Goetz, C. G.

AU - Tanner, C. M.

AU - Glantz, R.

AU - Goetz, C. G.

AU - Shannon, K. M.

AU - Tanner, C. M.

AU - Lieberman, A. N.

AU - Goldstein, M.

AU - Gopinathan, G.

AU - Lieberman, A. N.

AU - Leibowitz, N.

AU - Gopinathan, G.

AU - Hely, M. A.

AU - Morris, J. G.L.

AU - Rail, D. D.

AU - Nakanishi, T.

AU - Mizuno, Y.

AU - Goto, I.

AU - Nakanishi, T.

AU - Iwata, M.

AU - Goto, I.

AU - Rascol, A.

AU - Montastruc, J. L.

AU - Rascol, O.

AU - Rinne, U. K.

AU - Weiner, W. J.

AU - Factor, S. A.

AU - Sanchez-Ramos, J. R.

AU - Felten, D. L.

AU - Felten, S. Y.

AU - Fuller, R. W.

AU - Yoshikawa, T.

PY - 1995/3/1

Y1 - 1995/3/1

N2 - Three trials evaluated the efficacy and safety of pergolide.Eighty-six de novo patients and 314 patients already receiving levodopa were enrolled in an open-label study. Of the de novo patients, 47.5% showed a marked or moderate improvement and 32% showed a mild improvement. In the levodopa add-on group, 53.8% showed marked or moderate improvement and 36.3% showed mild improvement. In a short-term, double-blind study, the efficacy of pergolide was compared with that of bromocriptine. One hundred seventy-two patients were randomized to receive pergolide, and 173 were randomized to receive bromocriptine. In de novo patients, bromocriptine (n equals 49) and pergolide (n equals 49) demonstrated similar efficacy. However, significantly more levodopa-treated patients in the pergolide group, compared with the bromocriptine group, demonstrated marked or moderate improvements in several items of the rating scale score. In a long-term study, 151 of 314 patients receiving pergolide in combination with levodopa remained in the study for 3 years, and 127 for 4 years, and in these patients the initial improvement was maintained. In 18 of 62 de novo patients, the initial improvement was maintained for up to 3 years. These trials indicate that pergolide has efficacy in patients with Parkinson's disease, either as monotherapy or in combination with levodopa.

AB - Three trials evaluated the efficacy and safety of pergolide.Eighty-six de novo patients and 314 patients already receiving levodopa were enrolled in an open-label study. Of the de novo patients, 47.5% showed a marked or moderate improvement and 32% showed a mild improvement. In the levodopa add-on group, 53.8% showed marked or moderate improvement and 36.3% showed mild improvement. In a short-term, double-blind study, the efficacy of pergolide was compared with that of bromocriptine. One hundred seventy-two patients were randomized to receive pergolide, and 173 were randomized to receive bromocriptine. In de novo patients, bromocriptine (n equals 49) and pergolide (n equals 49) demonstrated similar efficacy. However, significantly more levodopa-treated patients in the pergolide group, compared with the bromocriptine group, demonstrated marked or moderate improvements in several items of the rating scale score. In a long-term study, 151 of 314 patients receiving pergolide in combination with levodopa remained in the study for 3 years, and 127 for 4 years, and in these patients the initial improvement was maintained. In 18 of 62 de novo patients, the initial improvement was maintained for up to 3 years. These trials indicate that pergolide has efficacy in patients with Parkinson's disease, either as monotherapy or in combination with levodopa.

UR - http://www.scopus.com/inward/record.url?scp=0042120031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042120031&partnerID=8YFLogxK

U2 - 10.1212/wnl.45.3_suppl_3.s13

DO - 10.1212/wnl.45.3_suppl_3.s13

M3 - Article

C2 - 7715792

AN - SCOPUS:0042120031

SN - 0028-3878

VL - 45

SP - S13-S21

JO - Neurology

JF - Neurology

IS - 3

ER -

Pergolide in the treatment of parkinson's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this